Cross-Regional Comparison of CDCA8 Gene Expression and Prognosis in Glioma Patients: A Meta-Analysis Based on CGGA and TCGA Databases

Objective: CDCA8 is frequently overexpressed in malignant tumors and linked to poor prognosis. This study evaluated the prognostic significance of CDCA8 expression in glioma patients using the CGGA and TCGA datasets. Methods: Clinical and expression data of glioma patients from CGGA and TCGA were analyzed. CDCA8 expression was compared across subgroups based on tumor grade (GBM vs. LGG) and IDH mutation status, and meta-analyses were performed to assess inter-database differences. Results: This study included 1125 glioma patients from CGGA and TCGA. CDCA8 expression was higher in TCGA GBM (p < 0.001) but comparable between databases in LGG (p = 0.501). CGGA showed lower CDCA8 in IDH-mutant gliomas (p < 0.001), with no difference in IDH-wildtype cases (p = 0.154). CGGA patients had longer overall survival in all above subgroups. Meta-analysis found no significant prognostic association of CDCA8 in GBM, IDH-wildtype and IDH-mutant gliomas. In LGG, high CDCA8 was significantly linked to reduced adverse events (p < 0.001, OR = 0.22, 95% CI [0.11–0.43]). Conclusion: CDCA8 has grade-dependent prognostic roles in gliomas. Its overexpression correlates with poor prognosis in GBM but favorable outcomes in LGG. Inter-database variations support CDCA8 as a promising prognostic biomarker for LGG, and reflect the influences of regional, therapeutic and genetic factors.